<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00177047</url>
  </required_header>
  <id_info>
    <org_study_id>2004LS001</org_study_id>
    <secondary_id>MT2003-13</secondary_id>
    <secondary_id>0312M54569</secondary_id>
    <nct_id>NCT00177047</nct_id>
    <nct_alias>NCT00293306</nct_alias>
  </id_info>
  <brief_title>Autologous Transplant for Multiple Myeloma</brief_title>
  <official_title>Autologous Transplantation for Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of a regimen of melphalan and autologous stem cells for patients with&#xD;
      multiple myeloma. We hypothesize that this particular regimen will improve the survival of&#xD;
      these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Before starting treatment in this study, the bone marrow transplant (BMT) doctor will check&#xD;
      the subject's general health. Subjects will have the following tests and evaluations to find&#xD;
      out if they can participate:--Medical history and physical examination, including height and&#xD;
      weight.--Blood tests (approximately 4 - 5 tablespoons) --Urine tests--Chest&#xD;
      x-ray--Electrocardiogram (ECG or EKG)--Heart Scan (MUGA)--Pulmonary Function Test (PFT)--Bone&#xD;
      marrow biopsies and aspirates. --If Female subjects of child-bearing age will have a serum&#xD;
      pregnancy test performed. After eligible patients have been completely staged and exercised&#xD;
      consent, they may undergo one cycle of chemotherapy (cyclophosphamide and Mesna) and growth&#xD;
      factor (G-CSF) to effect cytoreduction and mobilization of PBSC for collection. All patients&#xD;
      will receive high-dose melphalan followed by an autologous stem cell transplant (SCT). Blood&#xD;
      tests will be performed frequently to evaluate the subject's response to treatment and&#xD;
      possible side effects of treatment. If necessary, platelet and red cell transfusions will be&#xD;
      given to maintain adequate levels and antibiotics will be given to treat or prevent&#xD;
      infection. Subjects may also require intravenous nutritional support and pain medications&#xD;
      during or after transplantation. The study coordinators will collect health information over&#xD;
      three years. They will collect information every week for 100 days, then at 6 months, 1 year,&#xD;
      2 years, and 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 20, 2004</start_date>
  <completion_date type="Actual">August 1, 2020</completion_date>
  <primary_completion_date type="Actual">August 1, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Achieving a Complete Response</measure>
    <time_frame>100 Days post transplant</time_frame>
    <description>Myeloma Response Definitions - Using International Uniform Response Criteria:&#xD;
Stringent Complete Response (sCR)requires, plus CR:&#xD;
Normal free light chain ratio&#xD;
Absence of clonal cells in bone marrow&#xD;
Complete Response (CR):&#xD;
Absence of the original monoclonal paraprotein&#xD;
&lt;5% plasma cells in a bone marrow aspirate and also on trephine bone biopsy&#xD;
No increase in size or number of lytic bone lesions&#xD;
Disappearance of soft tissue plasmacytomas.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Achieving a Complete Response</measure>
    <time_frame>6 months post transplant</time_frame>
    <description>Myeloma Response Definitions - Using International Uniform Response Criteria:&#xD;
Stringent Complete Response (sCR)requires, plus CR:&#xD;
Normal free light chain ratio&#xD;
Absence of clonal cells in bone marrow&#xD;
Complete Response (CR):&#xD;
Absence of the original monoclonal paraprotein&#xD;
&lt;5% plasma cells in a bone marrow aspirate and also on trephine bone biopsy&#xD;
No increase in size or number of lytic bone lesions&#xD;
Disappearance of soft tissue plasmacytomas.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Achieving a Complete Response</measure>
    <time_frame>12 months post transplant</time_frame>
    <description>Myeloma Response Definitions - Using International Uniform Response Criteria:&#xD;
Stringent Complete Response (sCR)requires, plus CR:&#xD;
Normal free light chain ratio&#xD;
Absence of clonal cells in bone marrow&#xD;
Complete Response (CR):&#xD;
Absence of the original monoclonal paraprotein&#xD;
&lt;5% plasma cells in a bone marrow aspirate and also on trephine bone biopsy&#xD;
No increase in size or number of lytic bone lesions&#xD;
Disappearance of soft tissue plasmacytomas.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Extended Disease-free Survival</measure>
    <time_frame>36 Months</time_frame>
    <description>Extended disease free survival will be defined as percentage of patients surviving more than 36 months without relapse or disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Overall Survival</measure>
    <time_frame>1 year</time_frame>
    <description>The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer. Also called survival rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer. Also called survival rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Overall Survival</measure>
    <time_frame>3 years</time_frame>
    <description>The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer. Also called survival rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of Participants Experiencing Transplant Related Mortality</measure>
    <time_frame>1 year</time_frame>
    <description>In the field of transplantation, toxicity is high and all deaths without previous relapse or progression are usually considered as related to transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Incidence of Relapse</measure>
    <time_frame>1 year</time_frame>
    <description>The return of disease after its apparent recovery/cessation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Disease Progression</measure>
    <time_frame>1 year</time_frame>
    <description>Myeloma Response Definitions - Using International Uniform Response Criteria:&#xD;
Progressive Disease (PD)&#xD;
For patients not in CR or sCR, progressive disease requires one or more of the following:&#xD;
&gt;25% increase in the level of the serum monoclonal paraprotein, which must also be an absolute increase of at least 0.5 g/dL.&#xD;
&gt;25% increase in 24-hour urine protein electrophoresis, which must also be an absolute increase of at least 200 mg/24 hours.&#xD;
Absolute increase in the difference between involved and uninvolved FLC levels (absolute increase must be &gt;10 mg/dl), only in patients without measurable paraprotein in the serum and urine.&#xD;
&gt;25% increase in plasma cells in a bone marrow aspirate or on trephine biopsy, which must also be an absolute increase of at least 10%.&#xD;
Definite increase in the size of existing bone lesions or soft tissue plasmacytomas.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>1 year</time_frame>
    <description>Mean number of days among patients progressing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Relapse</measure>
    <time_frame>1 year</time_frame>
    <description>Mean number of days among patients relapsing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Absolute Neutrophil Recovery</measure>
    <time_frame>Day 42</time_frame>
    <description>Hematologic recovery is defined by absolute neutrophil count (ANC) &gt;2500/μl and platelets &gt; 100,000/μl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Attainment of CR</measure>
    <time_frame>12 months post transplant</time_frame>
    <description>Mean (STD) among patients achieving complete remission (CR)&#xD;
Myeloma Response Definitions - Using International Uniform Response Criteria:&#xD;
Complete Response (CR):&#xD;
Absence of the original monoclonal paraprotein&#xD;
&lt;5% plasma cells in a bone marrow aspirate and also on trephine bone biopsy&#xD;
No increase in size or number of lytic bone lesions&#xD;
Disappearance of soft tissue plasmacytomas</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Attainment of CR+PR</measure>
    <time_frame>12 months post transplant</time_frame>
    <description>Mean (STD) among patients achieving complete remission (CR) and partial remission (PR)&#xD;
Myeloma Response Definitions - Using International Uniform Response Criteria:&#xD;
Complete Response (CR):&#xD;
Absence of the original monoclonal paraprotein&#xD;
&lt;5% plasma cells in a bone marrow aspirate and also on trephine bone biopsy&#xD;
No increase in size or number of lytic bone lesions&#xD;
Disappearance of soft tissue plasmacytomas.&#xD;
Partial Response (PR):&#xD;
Greater than or equal to 50% reduction in the level of the serum monoclonal paraprotein and/or reduction in 24 hour urinary monoclonal paraprotein either by greater than or equal to 90% or to &lt;200 mg/24 hours in light chain disease.&#xD;
If the only measurable non-bone marrow parameter is FLC, greater than or equal to 50% reduction in the difference between involved and uninvolved FLC levels or a 50% decrease in level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Maintenance Treatment</measure>
    <time_frame>During study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dropout Rate From Maintenance Therapy</measure>
    <time_frame>Post transplant phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Toxicities</measure>
    <time_frame>By first 100 days</time_frame>
    <description>Occurrence of toxicities by first 100 days of transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Infections</measure>
    <time_frame>By first 100 days</time_frame>
    <description>Occurrence of infections in the patients by the first 100 days of transplant</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">363</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Chemotherapy and Transplant Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m^2). Post-transplant maintenance therapy is then prescribed if appropriate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Transplant</intervention_name>
    <description>As part of the stem cell transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease, such as cancer. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover.</description>
    <arm_group_label>Chemotherapy and Transplant Treatment</arm_group_label>
    <other_name>Bone Marrow Transplant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide + Mesna</intervention_name>
    <description>Cyclophosphamide: 4mg/m^2 + Mesna. Mesna is used to reduce the undesired side effects of certain chemotherapy drugs.</description>
    <arm_group_label>Chemotherapy and Transplant Treatment</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Administered intravenously 200 mg/m^2</description>
    <arm_group_label>Chemotherapy and Transplant Treatment</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Granulocyte-colony stimulating factor</intervention_name>
    <description>Administered intravenously 10 ug/kg/day pretransplant then 5 ug/kg/day post-transplant.</description>
    <arm_group_label>Chemotherapy and Transplant Treatment</arm_group_label>
    <other_name>G-CSF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients meeting the Durie and Salmon criteria for initial diagnosis of multiple&#xD;
             myeloma, requiring therapy and meeting one of the following:&#xD;
&#xD;
               -  After initial therapy in either first complete or partial remission or no&#xD;
                  objective response&#xD;
&#xD;
               -  After achieving initial response and later disease progression, patient will be&#xD;
                  eligible after subsequent therapy upon achievement of either complete or partial&#xD;
                  response&#xD;
&#xD;
          -  Is not eligible or has refused any protocols of higher priority&#xD;
&#xD;
          -  18 - 75 years of age&#xD;
&#xD;
          -  Adequate organ function defined as:&#xD;
&#xD;
               -  Hematologic: hemoglobin ≥ 8 gm/dl (untransfused), white blood cells (WBC) ≥&#xD;
                  3000/μl, absolute neutrophil count (ANC) ≥ 1500/μl, platelets ≥ 100,000/μl&#xD;
                  (untransfused)&#xD;
&#xD;
               -  Cardiac: no active ischemia, left ventricular ejection fraction &gt; 45% by MUGA&#xD;
                  scan&#xD;
&#xD;
               -  Hepatic: bilirubin &lt; 2.0 mg/dl, ALT &lt; 3x the upper limit of normal&#xD;
&#xD;
               -  Pulmonary: FEV1-Forced Expiratory Volume in One Second AND Forced vital capacity&#xD;
                  (FVC) &gt;50% predicted and Carbon Monoxide Diffusing Capacity (DLCO) (corrected) &gt;&#xD;
                  50% predicted&#xD;
&#xD;
               -  Performance status: Karnofsky performance of &gt; 80%.&#xD;
&#xD;
          -  Free of active uncontrolled infection at the time of study entry.&#xD;
&#xD;
          -  At time of study enrollment &gt; 4 weeks from prior myelosuppressive chemotherapy; and &gt;&#xD;
             6 weeks from prior nitrosoureas.&#xD;
&#xD;
          -  Patients must exercise informed voluntary consent and sign a consent form approved by&#xD;
             the University of Minnesota IRB: Human Subjects Committee.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients will be ineligible if they have advanced myeloma refractory and unresponsive&#xD;
             to salvage chemotherapy regimens.&#xD;
&#xD;
          -  Female patients who are pregnant (positive b-HCG) or breastfeeding will be excluded&#xD;
             from study entry. In addition fertile men or women unwilling to use contraceptive&#xD;
             techniques during and for 12 months following treatment, particularly after&#xD;
             thalidomide will also be excluded from study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudio Brunstein, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Masonic Cancer Center, University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <results_first_submitted>August 19, 2021</results_first_submitted>
  <results_first_submitted_qc>November 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 9, 2021</results_first_posted>
  <last_update_submitted>November 7, 2021</last_update_submitted>
  <last_update_submitted_qc>November 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stem cell transplantation</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>multiple myeloma</keyword>
  <keyword>autologous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 23, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT00177047/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Chemotherapy and Transplant Treatment</title>
          <description>Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m^2). Post-transplant maintenance therapy is then prescribed if appropriate.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="363"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="363"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Chemotherapy and Transplant Treatment</title>
          <description>Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m^2). Post-transplant maintenance therapy is then prescribed if appropriate.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="363"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="257"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="166"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="313"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="304"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Achieving a Complete Response</title>
        <description>Myeloma Response Definitions - Using International Uniform Response Criteria:&#xD;
Stringent Complete Response (sCR)requires, plus CR:&#xD;
Normal free light chain ratio&#xD;
Absence of clonal cells in bone marrow&#xD;
Complete Response (CR):&#xD;
Absence of the original monoclonal paraprotein&#xD;
&lt;5% plasma cells in a bone marrow aspirate and also on trephine bone biopsy&#xD;
No increase in size or number of lytic bone lesions&#xD;
Disappearance of soft tissue plasmacytomas.</description>
        <time_frame>100 Days post transplant</time_frame>
        <population>173 participants were not evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy and Transplant Treatment</title>
            <description>Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m^2). Post-transplant maintenance therapy is then prescribed if appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving a Complete Response</title>
          <description>Myeloma Response Definitions - Using International Uniform Response Criteria:&#xD;
Stringent Complete Response (sCR)requires, plus CR:&#xD;
Normal free light chain ratio&#xD;
Absence of clonal cells in bone marrow&#xD;
Complete Response (CR):&#xD;
Absence of the original monoclonal paraprotein&#xD;
&lt;5% plasma cells in a bone marrow aspirate and also on trephine bone biopsy&#xD;
No increase in size or number of lytic bone lesions&#xD;
Disappearance of soft tissue plasmacytomas.</description>
          <population>173 participants were not evaluable</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Achieving a Complete Response</title>
        <description>Myeloma Response Definitions - Using International Uniform Response Criteria:&#xD;
Stringent Complete Response (sCR)requires, plus CR:&#xD;
Normal free light chain ratio&#xD;
Absence of clonal cells in bone marrow&#xD;
Complete Response (CR):&#xD;
Absence of the original monoclonal paraprotein&#xD;
&lt;5% plasma cells in a bone marrow aspirate and also on trephine bone biopsy&#xD;
No increase in size or number of lytic bone lesions&#xD;
Disappearance of soft tissue plasmacytomas.</description>
        <time_frame>6 months post transplant</time_frame>
        <population>54 participants were not evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy and Transplant Treatment</title>
            <description>Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m^2). Post-transplant maintenance therapy is then prescribed if appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving a Complete Response</title>
          <description>Myeloma Response Definitions - Using International Uniform Response Criteria:&#xD;
Stringent Complete Response (sCR)requires, plus CR:&#xD;
Normal free light chain ratio&#xD;
Absence of clonal cells in bone marrow&#xD;
Complete Response (CR):&#xD;
Absence of the original monoclonal paraprotein&#xD;
&lt;5% plasma cells in a bone marrow aspirate and also on trephine bone biopsy&#xD;
No increase in size or number of lytic bone lesions&#xD;
Disappearance of soft tissue plasmacytomas.</description>
          <population>54 participants were not evaluable</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Achieving a Complete Response</title>
        <description>Myeloma Response Definitions - Using International Uniform Response Criteria:&#xD;
Stringent Complete Response (sCR)requires, plus CR:&#xD;
Normal free light chain ratio&#xD;
Absence of clonal cells in bone marrow&#xD;
Complete Response (CR):&#xD;
Absence of the original monoclonal paraprotein&#xD;
&lt;5% plasma cells in a bone marrow aspirate and also on trephine bone biopsy&#xD;
No increase in size or number of lytic bone lesions&#xD;
Disappearance of soft tissue plasmacytomas.</description>
        <time_frame>12 months post transplant</time_frame>
        <population>55 participants were not evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy and Transplant Treatment</title>
            <description>Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m^2). Post-transplant maintenance therapy is then prescribed if appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving a Complete Response</title>
          <description>Myeloma Response Definitions - Using International Uniform Response Criteria:&#xD;
Stringent Complete Response (sCR)requires, plus CR:&#xD;
Normal free light chain ratio&#xD;
Absence of clonal cells in bone marrow&#xD;
Complete Response (CR):&#xD;
Absence of the original monoclonal paraprotein&#xD;
&lt;5% plasma cells in a bone marrow aspirate and also on trephine bone biopsy&#xD;
No increase in size or number of lytic bone lesions&#xD;
Disappearance of soft tissue plasmacytomas.</description>
          <population>55 participants were not evaluable</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Extended Disease-free Survival</title>
        <description>Extended disease free survival will be defined as percentage of patients surviving more than 36 months without relapse or disease progression.</description>
        <time_frame>36 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy and Transplant Treatment</title>
            <description>Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m^2). Post-transplant maintenance therapy is then prescribed if appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Extended Disease-free Survival</title>
          <description>Extended disease free survival will be defined as percentage of patients surviving more than 36 months without relapse or disease progression.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Overall Survival</title>
        <description>The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer. Also called survival rate.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy and Transplant Treatment</title>
            <description>Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m^2). Post-transplant maintenance therapy is then prescribed if appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Overall Survival</title>
          <description>The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer. Also called survival rate.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Overall Survival</title>
        <description>The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer. Also called survival rate.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy and Transplant Treatment</title>
            <description>Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m^2). Post-transplant maintenance therapy is then prescribed if appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Overall Survival</title>
          <description>The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer. Also called survival rate.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Overall Survival</title>
        <description>The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer. Also called survival rate.</description>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy and Transplant Treatment</title>
            <description>Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m^2). Post-transplant maintenance therapy is then prescribed if appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Overall Survival</title>
          <description>The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer. Also called survival rate.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Count of Participants Experiencing Transplant Related Mortality</title>
        <description>In the field of transplantation, toxicity is high and all deaths without previous relapse or progression are usually considered as related to transplantation.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy and Transplant Treatment</title>
            <description>Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m^2). Post-transplant maintenance therapy is then prescribed if appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Participants Experiencing Transplant Related Mortality</title>
          <description>In the field of transplantation, toxicity is high and all deaths without previous relapse or progression are usually considered as related to transplantation.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Incidence of Relapse</title>
        <description>The return of disease after its apparent recovery/cessation.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy and Transplant Treatment</title>
            <description>Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m^2). Post-transplant maintenance therapy is then prescribed if appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Incidence of Relapse</title>
          <description>The return of disease after its apparent recovery/cessation.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Disease Progression</title>
        <description>Myeloma Response Definitions - Using International Uniform Response Criteria:&#xD;
Progressive Disease (PD)&#xD;
For patients not in CR or sCR, progressive disease requires one or more of the following:&#xD;
&gt;25% increase in the level of the serum monoclonal paraprotein, which must also be an absolute increase of at least 0.5 g/dL.&#xD;
&gt;25% increase in 24-hour urine protein electrophoresis, which must also be an absolute increase of at least 200 mg/24 hours.&#xD;
Absolute increase in the difference between involved and uninvolved FLC levels (absolute increase must be &gt;10 mg/dl), only in patients without measurable paraprotein in the serum and urine.&#xD;
&gt;25% increase in plasma cells in a bone marrow aspirate or on trephine biopsy, which must also be an absolute increase of at least 10%.&#xD;
Definite increase in the size of existing bone lesions or soft tissue plasmacytomas.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy and Transplant Treatment</title>
            <description>Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m^2). Post-transplant maintenance therapy is then prescribed if appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Disease Progression</title>
          <description>Myeloma Response Definitions - Using International Uniform Response Criteria:&#xD;
Progressive Disease (PD)&#xD;
For patients not in CR or sCR, progressive disease requires one or more of the following:&#xD;
&gt;25% increase in the level of the serum monoclonal paraprotein, which must also be an absolute increase of at least 0.5 g/dL.&#xD;
&gt;25% increase in 24-hour urine protein electrophoresis, which must also be an absolute increase of at least 200 mg/24 hours.&#xD;
Absolute increase in the difference between involved and uninvolved FLC levels (absolute increase must be &gt;10 mg/dl), only in patients without measurable paraprotein in the serum and urine.&#xD;
&gt;25% increase in plasma cells in a bone marrow aspirate or on trephine biopsy, which must also be an absolute increase of at least 10%.&#xD;
Definite increase in the size of existing bone lesions or soft tissue plasmacytomas.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression</title>
        <description>Mean number of days among patients progressing</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy and Transplant Treatment</title>
            <description>Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m^2). Post-transplant maintenance therapy is then prescribed if appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression</title>
          <description>Mean number of days among patients progressing</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.4" spread="109.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Relapse</title>
        <description>Mean number of days among patients relapsing</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy and Transplant Treatment</title>
            <description>Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m^2). Post-transplant maintenance therapy is then prescribed if appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Relapse</title>
          <description>Mean number of days among patients relapsing</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182.9" spread="113.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Absolute Neutrophil Recovery</title>
        <description>Hematologic recovery is defined by absolute neutrophil count (ANC) &gt;2500/μl and platelets &gt; 100,000/μl</description>
        <time_frame>Day 42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy and Transplant Treatment</title>
            <description>Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m^2). Post-transplant maintenance therapy is then prescribed if appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Absolute Neutrophil Recovery</title>
          <description>Hematologic recovery is defined by absolute neutrophil count (ANC) &gt;2500/μl and platelets &gt; 100,000/μl</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Attainment of CR</title>
        <description>Mean (STD) among patients achieving complete remission (CR)&#xD;
Myeloma Response Definitions - Using International Uniform Response Criteria:&#xD;
Complete Response (CR):&#xD;
Absence of the original monoclonal paraprotein&#xD;
&lt;5% plasma cells in a bone marrow aspirate and also on trephine bone biopsy&#xD;
No increase in size or number of lytic bone lesions&#xD;
Disappearance of soft tissue plasmacytomas</description>
        <time_frame>12 months post transplant</time_frame>
        <population>Data was not available on everyone for this endpoint so could only evaluable for 308 out of 363 patients due to data for participants is not available as the EPIC system was not in place when this study was conducted and participants moved to different clinics we do not have follow-up details.</population>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy and Transplant Treatment</title>
            <description>Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m^2). Post-transplant maintenance therapy is then prescribed if appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Attainment of CR</title>
          <description>Mean (STD) among patients achieving complete remission (CR)&#xD;
Myeloma Response Definitions - Using International Uniform Response Criteria:&#xD;
Complete Response (CR):&#xD;
Absence of the original monoclonal paraprotein&#xD;
&lt;5% plasma cells in a bone marrow aspirate and also on trephine bone biopsy&#xD;
No increase in size or number of lytic bone lesions&#xD;
Disappearance of soft tissue plasmacytomas</description>
          <population>Data was not available on everyone for this endpoint so could only evaluable for 308 out of 363 patients due to data for participants is not available as the EPIC system was not in place when this study was conducted and participants moved to different clinics we do not have follow-up details.</population>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Attainment of CR+PR</title>
        <description>Mean (STD) among patients achieving complete remission (CR) and partial remission (PR)&#xD;
Myeloma Response Definitions - Using International Uniform Response Criteria:&#xD;
Complete Response (CR):&#xD;
Absence of the original monoclonal paraprotein&#xD;
&lt;5% plasma cells in a bone marrow aspirate and also on trephine bone biopsy&#xD;
No increase in size or number of lytic bone lesions&#xD;
Disappearance of soft tissue plasmacytomas.&#xD;
Partial Response (PR):&#xD;
Greater than or equal to 50% reduction in the level of the serum monoclonal paraprotein and/or reduction in 24 hour urinary monoclonal paraprotein either by greater than or equal to 90% or to &lt;200 mg/24 hours in light chain disease.&#xD;
If the only measurable non-bone marrow parameter is FLC, greater than or equal to 50% reduction in the difference between involved and uninvolved FLC levels or a 50% decrease in level</description>
        <time_frame>12 months post transplant</time_frame>
        <population>55 patients were not evaluable Data was not available on everyone for this endpoint so could not evaluate all 363 patients</population>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy and Transplant Treatment</title>
            <description>Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m^2). Post-transplant maintenance therapy is then prescribed if appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Attainment of CR+PR</title>
          <description>Mean (STD) among patients achieving complete remission (CR) and partial remission (PR)&#xD;
Myeloma Response Definitions - Using International Uniform Response Criteria:&#xD;
Complete Response (CR):&#xD;
Absence of the original monoclonal paraprotein&#xD;
&lt;5% plasma cells in a bone marrow aspirate and also on trephine bone biopsy&#xD;
No increase in size or number of lytic bone lesions&#xD;
Disappearance of soft tissue plasmacytomas.&#xD;
Partial Response (PR):&#xD;
Greater than or equal to 50% reduction in the level of the serum monoclonal paraprotein and/or reduction in 24 hour urinary monoclonal paraprotein either by greater than or equal to 90% or to &lt;200 mg/24 hours in light chain disease.&#xD;
If the only measurable non-bone marrow parameter is FLC, greater than or equal to 50% reduction in the difference between involved and uninvolved FLC levels or a 50% decrease in level</description>
          <population>55 patients were not evaluable Data was not available on everyone for this endpoint so could not evaluate all 363 patients</population>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Maintenance Treatment</title>
        <time_frame>During study</time_frame>
        <population>Data not available for this outcome at our center, maintenance treatment data for participants is not available as the EPIC system was not in place when this study was conducted and participants moved to different clinics so follow-up details were no available.</population>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy and Transplant Treatment</title>
            <description>Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m^2). Post-transplant maintenance therapy is then prescribed if appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Maintenance Treatment</title>
          <population>Data not available for this outcome at our center, maintenance treatment data for participants is not available as the EPIC system was not in place when this study was conducted and participants moved to different clinics so follow-up details were no available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dropout Rate From Maintenance Therapy</title>
        <time_frame>Post transplant phase</time_frame>
        <population>Data not available for this outcome at our center, maintenance treatment data for participants is not available as the EPIC system was not in place when this study was conducted and participants moved to different clinics so follow-up details were no available.</population>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy and Transplant Treatment</title>
            <description>Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m^2). Post-transplant maintenance therapy is then prescribed if appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Dropout Rate From Maintenance Therapy</title>
          <population>Data not available for this outcome at our center, maintenance treatment data for participants is not available as the EPIC system was not in place when this study was conducted and participants moved to different clinics so follow-up details were no available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Toxicities</title>
        <description>Occurrence of toxicities by first 100 days of transplant</description>
        <time_frame>By first 100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy and Transplant Treatment</title>
            <description>Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m^2). Post-transplant maintenance therapy is then prescribed if appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Toxicities</title>
          <description>Occurrence of toxicities by first 100 days of transplant</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Infections</title>
        <description>Occurrence of infections in the patients by the first 100 days of transplant</description>
        <time_frame>By first 100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy and Transplant Treatment</title>
            <description>Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m^2). Post-transplant maintenance therapy is then prescribed if appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Infections</title>
          <description>Occurrence of infections in the patients by the first 100 days of transplant</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Chemotherapy and Transplant Treatment</title>
          <description>Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m^2). Post-transplant maintenance therapy is then prescribed if appropriate.&#xD;
Stem Cell Transplant: As part of the stem cell transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease, such as cancer. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover.&#xD;
Cyclophosphamide + Mesna: Cyclophosphamide: 4mg/m^2 + Mesna. Mesna is used to reduce the undesired side effects of certain chemotherapy drugs.&#xD;
Melphalan: Administered intravenously 200 mg/m^2&#xD;
Granulocyte-colony stimulating factor: Administered intravenously 10 ug/kg/day pretransplant then 5 ug/kg/day post-transplant.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>M-spike increase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="194" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Cytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Artrial fibrillation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Congestive heart failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Heart abnormality</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Left vertricular hypertrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Low Ejection fraction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Plueral effusions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>stent placement for occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing loss</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Eye hemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Ocular muscle fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>bowl obstruction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Epigastric pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>GI bleed</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>GI toxicity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Engraftment syndrome</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Liver parenchymal disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="246" subjects_affected="140" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="77" subjects_affected="54" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated troponin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Transminitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle tear</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Physical Deconditioning</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Akinesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Neurotoxicity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hallucinations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Renal calculus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Renal insufficiency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Chest opacities</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Intubation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Rashes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>skin; stevens Johnson syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Left hio hemiarhroplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Blood clot</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr.Claudio G. Brunstein MD, PhD</name_or_title>
      <organization>Masonic Cancer Center, University of Minnesota</organization>
      <phone>612-625-3918</phone>
      <email>bruns072@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

